ve303

Cell therapyexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Nov 28, 2017 (NCT04236778)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06237452Phase 3May 20, 2024Vedanta Biosciences, Inc.
NCT04899115Phase 2Aug 6, 2021American Association for the Study of Liver Diseases, American College of Gastroenterology, University of Michigan, Vedanta Biosciences, Inc.
NCT03788434Phase 2Feb 8, 2018Vedanta Biosciences, Inc.
NCT04236778Phase 1Nov 28, 2017Vedanta Biosciences, Inc.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Vedanta Biosciences, Inc.For profit4332017
American Association for the Study of Liver DiseasesAcademic/Hospital1012021
American College of GastroenterologyAcademic/Hospital1012021
University of MichiganAcademic/Hospital1112021
4 organizations
Page 1 / 1